243 related articles for article (PubMed ID: 26616421)
1. Folate metabolic pathway single nucleotide polymorphisms: a predictive pharmacogenetic marker of methotrexate response in Indian (Asian) patients with rheumatoid arthritis.
Ghodke-Puranik Y; Puranik AS; Shintre P; Joshi K; Patwardhan B; Lamba J; Niewold TB; Chopra A
Pharmacogenomics; 2015 Dec; 16(18):2019-34. PubMed ID: 26616421
[TBL] [Abstract][Full Text] [Related]
2. Pharmacogenetic polymorphisms contributing to toxicity induced by methotrexate in the southern Spanish population with rheumatoid arthritis.
Plaza-Plaza JC; Aguilera M; Cañadas-Garre M; Chemello C; González-Utrilla A; Faus Dader MJ; Calleja MA
OMICS; 2012 Nov; 16(11):589-95. PubMed ID: 23095111
[TBL] [Abstract][Full Text] [Related]
3. Genetic Determinants of Methotrexate Toxicity in Tunisian Patients with Rheumatoid Arthritis: A Study of Polymorphisms Involved in the MTX Metabolic Pathway.
Chaabane S; Marzouk S; Akrout R; Ben Hamad M; Achour Y; Rebai A; Keskes L; Fourati H; Bahloul Z; Maalej A
Eur J Drug Metab Pharmacokinet; 2016 Aug; 41(4):385-93. PubMed ID: 26077125
[TBL] [Abstract][Full Text] [Related]
4. SLC19A1, SLC46A1 and SLCO1B1 polymorphisms as predictors of methotrexate-related toxicity in Portuguese rheumatoid arthritis patients.
Lima A; Bernardes M; Azevedo R; Monteiro J; Sousa H; Medeiros R; Seabra V
Toxicol Sci; 2014 Nov; 142(1):196-209. PubMed ID: 25124723
[TBL] [Abstract][Full Text] [Related]
5. Common polymorphisms in the folate pathway predict efficacy of combination regimens containing methotrexate and sulfasalazine in early rheumatoid arthritis.
James HM; Gillis D; Hissaria P; Lester S; Somogyi AA; Cleland LG; Proudman SM
J Rheumatol; 2008 Apr; 35(4):562-71. PubMed ID: 18322994
[TBL] [Abstract][Full Text] [Related]
6. The association between reduced folate carrier-1 gene 80G/A polymorphism and methotrexate efficacy or methotrexate related-toxicity in rheumatoid arthritis: A meta-analysis.
Li X; Hu M; Li W; Gu L; Chen M; Ding H; Vanarsa K; Du Y
Int Immunopharmacol; 2016 Sep; 38():8-15. PubMed ID: 27233001
[TBL] [Abstract][Full Text] [Related]
7. Do SNPs in folate pharmacokinetic pathway alter levels of intracellular methotrexate polyglutamates and affect response? A prospective study in Indian patients.
Sandhu A; Ahmad S; Kaur J; Bhatnagar A; Dhawan V; Dhir V
Clin Rheumatol; 2018 Dec; 37(12):3221-3228. PubMed ID: 30022368
[TBL] [Abstract][Full Text] [Related]
8. Effect of genetic polymorphisms in the folate pathway on methotrexate therapy in rheumatic diseases.
Stamp LK; Roberts RL
Pharmacogenomics; 2011 Oct; 12(10):1449-63. PubMed ID: 22008049
[TBL] [Abstract][Full Text] [Related]
9. Association Between MTHFR C677T Polymorphism and Methotrexate Treatment Outcome in Rheumatoid Arthritis Patients: A Systematic Review and Meta-Analysis.
Shao W; Yuan Y; Li Y
Genet Test Mol Biomarkers; 2017 May; 21(5):275-285. PubMed ID: 28277784
[TBL] [Abstract][Full Text] [Related]
10. Thymidylate synthase genetic polymorphism and plasma total homocysteine level in a group of Turkish patients with rheumatoid arthritis: relationship with disease activity and methotrexate toxicity.
Borman P; Taşbaş Ö; Karabulut H; Tukun A; Yorgancıoğlu R
Rev Bras Reumatol; 2015; 55(6):485-92. PubMed ID: 25687398
[TBL] [Abstract][Full Text] [Related]
11. Factors Predicting the Therapeutic Response to Methotrexate in Japanese Patients with Rheumatoid Arthritis: A Hospital-Based Cohort Study.
Hakamata J; Kaneko Y; Shimizu M; Yamaoka K; Maruyama J; Takeuchi T; Mochizuki M; Hashiguchi M
Biol Pharm Bull; 2018; 41(9):1414-1422. PubMed ID: 30175777
[TBL] [Abstract][Full Text] [Related]
12. Reduced folate carrier-1 80G>A polymorphism affects methotrexate treatment outcome in rheumatoid arthritis.
Drozdzik M; Rudas T; Pawlik A; Gornik W; Kurzawski M; Herczynska M
Pharmacogenomics J; 2007 Dec; 7(6):404-7. PubMed ID: 17325736
[TBL] [Abstract][Full Text] [Related]
13. Homocysteine and folate status in methotrexate-treated patients with rheumatoid arthritis.
van Ede AE; Laan RF; Blom HJ; Boers GH; Haagsma CJ; Thomas CM; De Boo TM; van de Putte LB
Rheumatology (Oxford); 2002 Jun; 41(6):658-65. PubMed ID: 12048292
[TBL] [Abstract][Full Text] [Related]
14. Methotrexate (MTX) pathway gene polymorphisms and their effects on MTX toxicity in Caucasian and African American patients with rheumatoid arthritis.
Ranganathan P; Culverhouse R; Marsh S; Mody A; Scott-Horton TJ; Brasington R; Joseph A; Reddy V; Eisen S; McLeod HL
J Rheumatol; 2008 Apr; 35(4):572-9. PubMed ID: 18381794
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and toxicity of methotrexate in early rheumatoid arthritis are associated with single-nucleotide polymorphisms in genes coding for folate pathway enzymes.
Wessels JA; de Vries-Bouwstra JK; Heijmans BT; Slagboom PE; Goekoop-Ruiterman YP; Allaart CF; Kerstens PJ; van Zeben D; Breedveld FC; Dijkmans BA; Huizinga TW; Guchelaar HJ
Arthritis Rheum; 2006 Apr; 54(4):1087-95. PubMed ID: 16572443
[TBL] [Abstract][Full Text] [Related]
16. A single nucleotide polymorphism of reduced folate carrier 1 predicts methotrexate efficacy in Japanese patients with rheumatoid arthritis.
Hayashi H; Tazoe Y; Tsuboi S; Horino M; Morishita M; Arai T; Ohshima M; Matsuyama T; Kosuge K; Yamada H; Tsuji D; Inoue K; Itoh K
Drug Metab Pharmacokinet; 2013; 28(2):164-8. PubMed ID: 22971639
[TBL] [Abstract][Full Text] [Related]
17. 2756GG genotype of methionine synthase reductase gene is more prevalent in rheumatoid arthritis patients treated with methotrexate and is associated with methotrexate-induced nodulosis.
Berkun Y; Abou Atta I; Rubinow A; Orbach H; Levartovsky D; Aamar S; Arbel O; Dresner-Pollak R; Friedman G; Ben-Yehuda A
J Rheumatol; 2007 Aug; 34(8):1664-9. PubMed ID: 17611986
[TBL] [Abstract][Full Text] [Related]
18. Reduced folate carrier-1 80G > A gene polymorphism is not associated with methotrexate treatment response in South Indian Tamils with rheumatoid arthritis.
Muralidharan N; Mariaselvam CM; Mithun CB; Negi VS
Clin Rheumatol; 2016 Apr; 35(4):879-85. PubMed ID: 25771854
[TBL] [Abstract][Full Text] [Related]
19. Membrane-Spanning Protein Genetic Polymorphisms Related to Methotrexate Therapeutic Outcomes in a Chinese Rheumatoid Arthritis Population.
Lv S; Fan H; Yang H; Huang J; Li J; Shu X; Zhang L; Xu Y; Li X; Zuo J; Lv C; Kong X; Xiao C
J Clin Pharmacol; 2019 Nov; 59(11):1471-1476. PubMed ID: 31099054
[TBL] [Abstract][Full Text] [Related]
20. Clinical-pharmacogenetic predictive models for MTX discontinuation due to adverse events in rheumatoid arthritis.
Jenko B; Lusa L; Tomsic M; Praprotnik S; Dolzan V
Pharmacogenomics J; 2017 Oct; 17(5):412-418. PubMed ID: 27217051
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
